ArticleBiosensors2025
Labeled Bovine Serum Albumin as a Fluorescent Biosensor to Monitor the Stability of Lipid-Based Formulations.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the pharmaceutical field, lipid-based nanoparticles are extensively used for drug or vaccine delivery, particularly for treating respiratory disorders. However, their physico-chemical instability, particularly associated with lipid degradation through hydrolysis or oxidation, can affect their encapsulation properties. To monitor the stability of lipid-based formulations over time, we prepared acrylodan-labeled bovine serum albumin (here called albuminodan), and showed it is a fluorescent biosensor capable of concomitantly detect phospholipids as well as their degradation products, i.e., fatty acids and lysophospholipids. We demonstrated that this tool can be used to follow the distribution of lipids in an aqueous phase and hence could be suitable to characterize the hydrolysis of phospholipids in a lipid-based formulation to monitor the stability of nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.